Home
/
Atara Biotherapeutics, Inc.
/
Financials
/
Quarterly
Atara Biotherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Atara Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.45M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$17.58M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$98.15M
May 15, 2025
Q3
2025
Sep 30, 2024
$40.19M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$28.64M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$27.36M
May 15, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.30M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
$2.39M
Aug 11, 2025
Q3
2025
Jun 30, 2025
$2.39M
Nov 12, 2025
Q2
2025
Mar 31, 2025
$38.01M
Aug 11, 2025
Q3
2025
Mar 31, 2025
$38.01M
Nov 12, 2025
Q1
2025
Mar 31, 2025
$38.01M
May 15, 2025
Q3
2025
Sep 30, 2024
($21.91M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($19.05M)
Aug 11, 2025
Q3
2025
Jun 30, 2024
($19.05M)
Nov 12, 2025
Q3
2025
Mar 31, 2024
($31.75M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($31.75M)
May 15, 2025
Q2
2025
Mar 31, 2024
($31.75M)
Aug 11, 2025
Q3
2024
Sep 30, 2023
($69.80M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($71.11M)
Aug 12, 2024
Q3
2024
Jun 30, 2023
($71.11M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($74.77M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($74.77M)
May 9, 2024
Q3
2024
Mar 31, 2023
($74.77M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($84.09M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
$18.47M
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.57M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
$3.20M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$38.80M
May 15, 2025
Q3
2025
Sep 30, 2024
($21.76M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($18.23M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($31.25M)
May 15, 2025
Q3
2024
Sep 30, 2023
($69.61M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($71.41M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($75.02M)
May 9, 2024
Q3
2023
Sep 30, 2022
($84.62M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($32.13M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($88.22M)
May 8, 2023
Q3
2022
Sep 30, 2021
($84.81M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($84.00M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($78.25M)
May 5, 2022
Q3
2021
Sep 30, 2020
($74.71M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($77.95M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($74.70M)
May 4, 2021
Q3
2020
Sep 30, 2019
($72.56M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($75.54M)
Aug 5, 2020